These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1141 related articles for article (PubMed ID: 7202703)

  • 1. The quantitative structure-selectivity relationship of anthracycline antitumor activity and cardiac toxicity.
    Fink SI; Leo A; Yamakawa M; Hansch C; Quinn FR
    Farmaco Sci; 1980 Dec; 35(12):965-79. PubMed ID: 7202703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
    Menna P; Recalcati S; Cairo G; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships among daunorubicin and adriamycin analogs.
    Henry DW
    Cancer Treat Rep; 1979 May; 63(5):845-54. PubMed ID: 455326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QSAR of acridines. II. Features of nitracrine analogs for high anti-tumor activity and selectivity on mice, searched by PCA and MRA methods.
    Mazerska Z; Mazerski J; Ledóchowski A
    Anticancer Drug Des; 1990 May; 5(2):169-87. PubMed ID: 2357263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the structure of new anthracycline antibiotics on their biological properties.
    Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
    Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor antibiotics and low molecular weight immunomodifiers of microbial origin.
    Umezawa H
    Cancer Treat Rep; 1984 Jan; 68(1):137-44. PubMed ID: 6692425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of anthracyclines in the era of targeted therapy.
    Cortés-Funes H; Coronado C
    Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rodorubicin, a new tetraglycosidic anthracycline.
    Kraemer HP; Sedlacek HH
    Behring Inst Mitt; 1988 Apr; (82):216-30. PubMed ID: 3165634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination of anthracyclines with radiotherapy. Value and problems].
    Gindrey B; Rivière A; Abbatucci JS
    Pathol Biol (Paris); 1987 Jan; 35(1):54-60. PubMed ID: 3550614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of mtDNA lesions in anthracycline cardiotoxicity.
    Lebrecht D; Walker UA
    Cardiovasc Toxicol; 2007; 7(2):108-13. PubMed ID: 17652814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anthracycline-induced cardiotoxicity: monitoring and prevention of the lesion].
    Orditura M; De Vita F; Ciaramella F; Catalano G
    Ann Ital Med Int; 1994; 9(4):243-8. PubMed ID: 7893575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
    Robert J
    Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anthracycline cardiotoxicity: review].
    Ribera JM; Montserrat E; Rozman C
    Sangre (Barc); 1983; 28(1):54-68. PubMed ID: 6346540
    [No Abstract]   [Full Text] [Related]  

  • 15. Antitumor properties of selected 1,2,4-triazine derivatives.
    Mordarski M; Wieczorek J; Fiszer L; Nantka-Namirski P; Rykowski A
    Arch Immunol Ther Exp (Warsz); 1980; 28(5):717-25. PubMed ID: 7212979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential anticancer agents. XX. 2. Quantitative structure--activity relationships (QSAR) in aromatic nitrogen mustards area.
    Niculescu-Duvăz I; Stihi G; Crăescu T; Simon Z
    Neoplasma; 1980; 27(3):271-8. PubMed ID: 7453847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Jones RL
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
    Fourie J; Guziec F; Guziec L; Monterrosa C; Fiterman DJ; Begleiter A
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):191-203. PubMed ID: 14614574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthracycline associated cardiac toxicity in children with malignancies.
    Mohta R; Saxena A; Jain Y; Gupta S; Thavaraj V; Narain S; Arya LS
    Indian Pediatr; 2002 Jun; 39(6):549-55. PubMed ID: 12084948
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduction of adriamycin cardiotoxicity by enoximone.
    Bossa R; Bissoli M; Chiericozzi M; Cozzi R; Galatulas I; Salvatore G
    Anticancer Res; 1996; 16(1):141-3. PubMed ID: 8615599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.